# A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs

> **NCT06708611** · PHASE4 · WITHDRAWN · sponsor: **Sarfez Pharmaceuticals, Inc.**

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** torsemide

## Key facts

- **NCT ID:** NCT06708611
- **Lead sponsor:** Sarfez Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-15
- **Primary completion:** 2025-03-25
- **Final completion:** 2025-03-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Recruitment issues
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06708611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06708611, "A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06708611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*